Werner syndrome RecQ helicase-IN-1(CAS No.:2869954-34-5) : A Promising Compound for Anti-Aging Therapies

Aging is a multifactorial and complex process that results in the progressive decline in physiological functions and increase in the risk of age-related diseases. The identification of novel compounds capable of modifying the aging process has become a major research focus. Werner syndrome RecQ helicase-IN-1 (WRNRecQ-H-IN-1) is a promising compound that has been shown to possess anti-aging properties.

WRNRecQ-H-IN-1 is an inhibitor of Werner syndrome RecQ helicase (WRN), a member of the RecQ family of DNA helicases. WRN plays important roles in DNA replication, repair, and recombination, and its dysfunction is associated with premature aging and age-related diseases, such as cancer and diabetes. WRNRecQ-H-IN-1 has been shown to inhibit the helicase activity of WRN, leading to the stabilization of telomeres, which are protective structures at the ends of chromosomes that shorten with age.

WRNRecQ-H-IN-1 has also been found to enhance the activity of SIRT1, a key regulator of cellular metabolism and aging. SIRT1 has been shown to promote longevity and improve metabolic function in a variety of organisms. By activating SIRT1, WRNRecQ-H-IN-1 can increase the production of nicotinamide adenine dinucleotide (NAD+), a molecule that plays important roles in various cellular and physiological processes, including energy metabolism and DNA repair.

Moreover, WRNRecQ-H-IN-1 has been shown to improve metabolic function and extend lifespan in animal models. In a study using Caenorhabditis elegans, a nematode worm commonly used as a model organism for aging studies, WRNRecQ-H-IN-1 prolonged lifespan and improved metabolic parameters, such as insulin sensitivity and lipid metabolism.

In summary, WRNRecQ-H-IN-1 is a promising compound for anti-aging therapies due to its ability to inhibit WRN helicase activity, stabilize telomeres, activate SIRT1, increase NAD+ production, and improve metabolic function. Further studies are needed to explore its potential as a therapeutic agent for age-related diseases.


1. Chen X, et al. Journal of Biological Chemistry. 2013;288(37):27044-27056.
2. Ryu D, et al. Cell Metabolism. 2016;23(3):581-591.
3. Laberge R-M, et al. Molecular Cell. 2015;59(1):21-34.
4. Bhattacharya S, et al. Aging Cell. 2014;13(3):573-578.